Ivermectin and Cancer: Analyzing the Truth in the Shadow of a Nobel Prize

Ivermectin’s story begins not in a pharmaceutical company’s laboratory, but in soil near a golf course in Japan’s Shizuoka Prefecture . In the 1970s, while screening soil microorganisms, the Japanese microbiologist Satoshi Ōmuradiscovered a previously unidentified bacterial species: Streptomyces avermitilis. The compounds produced by this bacterium had an extraordinary paralyzing effect on parasites. Ōmura sent his samples to the American parasitologist William C. Campbell; Campbell and his team refined the compound, developing first “avermectin” and then its safer and more effective form, ivermectin.

The result was one of the greatest public health victories in medical history. In Africa and Latin America, river blindness (onchocerciasis) , which blinded millions, and elephantiasis (lymphatic filariasis) , which caused severe disabilities, were brought largely under control. Ōmura and Campbell shared the 2015 Nobel Prize in Physiology or Medicine.

This distinction is the key to understanding the rest of this article. Ivermectin paralyzes parasites by binding to glutamate-gated chloride channels in their nerve and muscle cells. Human cells do not have these channels, which explains the drug’s exceptional safety profile. Cancer, however, is not a parasite; it is a genetically altered version of the body’s own cells. A drug’s excellent action against a parasite does not mean it will work on mutations in human cells. These are different biological pathways.

The honest way to combat disinformation is to address the opposing claim not in a weakened form, but at its strongest . It is true that ivermectin has shown genuinely interesting effects in oncology laboratories:

A drug killing cells in a petri dish means almost nothing on its own. Bleach also kills cancer cells within seconds. The real question is: can the concentration required for this effect be reached in the human body without harming the patient?

For ivermectin, the answer is among the clearest facts in pharmacology. The concentrations reported to affect cancer cells in the laboratory are generally in the range of 2–10 micromolar (µM) . By contrast, the highest blood concentration achievable in humans with standard use is approximately 0.05 µM (50 nanomolar) . In other words, there is approximately a 100-fold gap . Even in studies of increased use in healthy volunteers, the ceiling remained at approximately 300 nanomolar, still far below the laboratory threshold.

An important detail here is that approximately 93% of ivermectin in the blood is bound to plasma proteins. The “free” fraction that can reach and act on a cell is only a tiny proportion of the measured total. The actual gap is therefore greater than 100-fold.

We now come to a rarely mentioned but perhaps decisive finding in this debate. Ivermectin is a poorly water-soluble (hydrophobic) molecule; its water solubility limit is approximately 1–5 µM. Notice that this range falls right within the concentrations found “effective” in laboratory experiments. In many experiments, therefore, the drug may not have fully dissolved in the liquid.

The implications are serious: many laboratory results circulated under the headline “Ivermectin kills cancer cells” may very likely have measured an experimental artifact rather than the drug’s biological effect . Broken glass can also destroy a cell; that does not make glass a “cancer drug.”

In science, turning an idea into a treatment is a stepwise journey. Here is ivermectin’s actual position on that ladder:

The narrative’s emotional core is this: “Pharmaceutical companies are hiding this treatment because it is cheap and off-patent.” Two separate facts refute this claim.

The second, more striking fact is a matter of logic. Tens of thousands of independent oncologists work worldwide; thousands conduct research at public universities with funding independent of pharmaceutical companies. More importantly: oncologists also develop cancer; oncologists’ mothers, fathers, and children also lose their lives to this disease. Concealing an inexpensive, readily available cure that genuinely works within such a large and competitive community—especially from people who would want it for their own families—is organizationally close to impossible.

History offers another example: during the COVID-19 pandemic, hydroxychloroquine rose through a similar “suppressed miracle” narrative, only for large randomized trials to show that it provided no benefit. The narrative follows the same template every time; only the molecule’s name changes.

A cancer diagnosis is one of the greatest moments of uncertainty in a person’s life. Turning toward a solution described as “cheap, natural, and concealed” at such a moment is not weakness, but a deeply human response. The problem lies not with the patient, but with the mechanism feeding that response.

According to a University of Florida study published in the Journal of Cancer Education, 93% of newly diagnosed cancer patients are exposed to at least one type of treatment misinformation. The study’s most notable finding is that most patients had not sought this information. Algorithms sense the diagnosis, people around the patient hear about it, and content starts flowing to the patient on its own. This is therefore not a problem of “curiosity,” but of exposure .

The cost of this exposure is tangible: delaying or refusing standard treatment. In oncology, delay is often an irreversible loss.

The idea that “it cannot hurt, so there is no harm in trying” is the most dangerous misconception here. Ivermectin can interact with the CYP3A4 enzyme system responsible for breaking down drugs in the liver, and with the P-glycoprotein transporter in the cell membrane. Many oncology drugs are processed through the same pathways.

The most insidious risk here is often the one that does not come to mind: not harm to the patient from the interaction itself, but having to interrupt the treatment that actually works because of the resulting side effects. You can also read our article on the risks of alternative products , where we discuss this subject in greater detail.

Ivermectin’s story, beginning beside a golf course and saving millions from blindness, is one of medical history’s brightest chapters. That discovery deserves respect. But using a Nobel-winning victory against parasites as a badge to hide behind an unproven cancer claim is unfair both to the discovery and to patients at their most vulnerable.

Oncology is genuinely undergoing a revolutionary era: targeted drugs, immunotherapies, and treatments personalized to the tumor’s genetic map. These advances may seem slow because each must pass a rigorous evidence process. But that slowness is not a flaw; it is a protective mechanism —one that protects you from spending time and hope on things that do not work.

Our course is evidence-based medicine. Hope is not the opposite of truth; hope endures when it is built on truth.

Editor’s note: This content is for general information only; it is not medical advice, a diagnosis, or a treatment recommendation. All data presented have been verified against primary sources and conveyed without direct quotation. There is no Phase 3 randomized evidence that ivermectin is effective in cancer treatment, and no regulatory agency (FDA, EMA, TİTCK) has approved it for a cancer indication. The laboratory and animal data presented do not constitute patient treatment; such data indicate associations and possibilities, not proof of clinical benefit. Comparisons of drug concentrations are based on published pharmacokinetic analyses. The subject remains scientifically disputed; publications also argue that effects may occur at achievable concentrations, and ongoing early-phase clinical trials have not concluded. This content will be updated when results are published. Using ivermectin alongside cancer treatments carries a serious risk of drug interactions and may delay effective treatment. This article does not recommend starting, stopping, or changing any medication; always share all products you use with your oncology team. Consult the physician who knows you for every decision concerning your health.